Overview

• Protective effect of MHT on bone fractures disappears within one year of discontinuation.
• Post-cessation fracture risk climbs above never users and peaks around three years after stopping.
• Risk levels return to parity with non-users by about ten years and decline further thereafter.
• Researchers analysed primary care records of 6 million women across 2,000 UK GP practices with up to 25 years of follow-up.
• Findings prompt calls for targeted bone density assessments and informed risk–benefit discussions at therapy cessation.